Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057549 · ClinicalTrials.gov registry record · Phase 4
Haloperidol vs Conventional Therapy for Gastroparesis
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT02057549 is a Phase 4 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 36 participants.
The verdict
NCT02057549, a Phase 4 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
Randomized controlled trial comparing haloperidol combined with conventional therapy and conventional therapy alone in patients with symptomatic gastroparesis.
Interventions
- DRUG Haloperidol
- DRUG Conventional Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02057549
The ClinicalTrials.gov registry entry for NCT02057549 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Haloperidol is the first listed.
NCT02057549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02057549 about?
NCT02057549 is a clinical study titled "Haloperidol vs Conventional Therapy for Gastroparesis". Randomized controlled trial comparing haloperidol combined with conventional therapy and conventional therapy alone in patients with symptomatic gastroparesis.
What is the current status of trial NCT02057549?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2012-11. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02057549?
The interventions under investigation include: Haloperidol (DRUG), Conventional Therapy (DRUG).
Who is sponsoring clinical trial NCT02057549?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.